Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-23T07:33:24.764Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of taurine on glycaemic, lipid and inflammatory profile in individuals with type 2 diabetes: study protocol of a randomised trial

Published online by Cambridge University Press:  01 September 2022

Greice Caletti ,
Monique Vargas Cardoso ,
Rafael Selbach Scheffel ,
Beatriz D. Schaan ,
Rosane Gomez  and
Patrícia Martins Bock Open the ORCID record for Patrícia Martins Bock [Opens in a new window]
Greice Caletti
Affiliation:
Universidade Federal do Rio Grande do Sul, Medical School, Porto Alegre, Brazil Hospital de Clínicas de Porto Alegre, Endocrine Division, Porto Alegre, Brazil
Monique Vargas Cardoso
Affiliation:
Faculdades Integradas de Taquara, Taquara, Brazil
Rafael Selbach Scheffel
Affiliation:
Universidade Federal do Rio Grande do Sul, Medical School, Porto Alegre, Brazil Hospital de Clínicas de Porto Alegre, Endocrine Division, Porto Alegre, Brazil Universidade Federal do Rio Grande do Sul, Departament of Pharmacology, Instituto de Ciências Básicas da Saúde, Porto Alegre, Brazil
Beatriz D. Schaan
Affiliation:
Universidade Federal do Rio Grande do Sul, Medical School, Porto Alegre, Brazil Hospital de Clínicas de Porto Alegre, Endocrine Division, Porto Alegre, Brazil
Rosane Gomez
Affiliation:
Universidade Federal do Rio Grande do Sul, Departament of Pharmacology, Instituto de Ciências Básicas da Saúde, Porto Alegre, Brazil
Patrícia Martins Bock*
Affiliation:
Universidade Federal do Rio Grande do Sul, Departament of Pharmacology, Instituto de Ciências Básicas da Saúde, Porto Alegre, Brazil Faculdades Integradas de Taquara, Taquara, Brazil
*
*Corresponding author: Patrícia Martins Bock, Email patriciabock74@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Type 2 diabetes mellitus (T2DM) is characterised by chronic hyperglycaemia. Despite the efficacy of conventional pharmacotherapy, some individuals do not reach glycaemic goals and require adjuvant therapies. Taurine, a semi-essential amino acid, decreases blood glucose and cholesterol levels in rodents and humans. However, glycated hemoglobin (HbA1c) has not been evaluated in randomised controlled trials after taurine treatment for more than 12 weeks. This study aims to evaluate the effect of taurine administration on glycaemic, lipid, inflammatory, anthropometric and dietary parameters in individuals with T2DM. A randomised, double-blind, placebo-controlled clinical trial will be conducted at the Clinical Research Center of a tertiary public hospital. Participants with T2DM (n 94) will be recruited and randomised to receive 3 g of taurine or placebo, twice/day, orally, for 12 weeks. Blood samples will be collected before and after 12 weeks of treatment, when HbA1c, fasting glucose, insulin, albuminuria, creatinine, total cholesterol and fractions, triglycerides, C-reactive protein, TNF-α, IL 1, 4, 5, 6, 10 and 13 will be evaluated. Anthropometric parameters and 24-hour food recall will also be evaluated. The study will evaluate the effect of taurine treatment on biochemical and anthropometric parameters in individuals with T2DM. These results will guide the decision-making to indicate taurine treatment as an adjunct in individuals with T2DM who have not reached their glycaemic goal.

Keywords

TaurineDiabetes mellitusCholesterolCytokinesGlycated hemoglobinHyperglycaemia
Type
Protocol Paper
Information
British Journal of Nutrition , Volume 129 , Issue 11 , 14 June 2023 , pp. 1871 - 1876
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Nutrition Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

WHO (2021) Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes (accessed August 2021).Google Scholar
Bertoluci, MC, Pimazoni-Netto, A, Pires, AC, et al. (2014) Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society. Diabetol Metab Syndr 6, 58.CrossRefGoogle ScholarPubMed
American Diabetes Association (2021) Facilitating Behavior change and well-being to improve health outcomes: standards of medical care in diabetes—2021. Diabetes Care 44, S53–72.CrossRefGoogle Scholar
Ferrari, F, Scheffel, RS, Martins, VM, et al. (2022) Glucagon-like peptide-1 receptor agonists in type 2 Diabetes mellitus and cardiovascular disease: the past, present, and future. Am J Cardiovasc Drugs 22, 363–383.CrossRefGoogle ScholarPubMed
Holman, RR, Paul, SK, Bethel, MA, et al. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359, 1577–1589.CrossRefGoogle ScholarPubMed
Schaffer, S & Kim, HW (2018) Effects and mechanisms of taurine as a therapeutic agent. Biomol Ther 26, 225–241.CrossRefGoogle ScholarPubMed
Maleki, V, Alizadeh, M, Esmaeili, F, et al. (2020) The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Amino Acids 52, 905–914.CrossRefGoogle ScholarPubMed
Caletti, G, Olguins, DB, Pedrollo, EF, et al. (2012) Antidepressant effect of taurine in diabetic rats. Amino Acids 43, 1525–1533.CrossRefGoogle ScholarPubMed
Caletti, G, Herrmann, AP, Pulcinelli, RR, et al. (2018) Taurine counteracts the neurotoxic effects of streptozotocin-induced diabetes in rats. Amino Acids 50, 95–104.CrossRefGoogle ScholarPubMed
Caletti, G, Almeida, FB, Agnes, G, et al. (2015) Antidepressant dose of taurine increases mRNA expression of GABAA receptor α2 subunit and BDNF in the hippocampus of diabetic rats. Behav Brain Res 283, 11–15.CrossRefGoogle ScholarPubMed
Winiarska, K, Szymanski, K, Gorniak, P, et al. (2009) Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 91, 261–270.CrossRefGoogle ScholarPubMed
Gomez, R, Caletti, G, Arbo, BD, et al. (2018) Acute intraperitoneal administration of taurine decreases the glycemia and reduces food intake in type 1 diabetic rats. Biomed Pharmacother 103, 1028–1034.CrossRefGoogle ScholarPubMed
Bae, M, Ahmed, K & Yim, J-E (2022) Beneficial effects of taurine on metabolic parameters in animals and humans. J Obes Metab Syndr 31, 134–146.CrossRefGoogle ScholarPubMed
Franconi, F, Bennardini, F, Mattana, A, et al. (1995) Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 61, 1115–1119.CrossRefGoogle ScholarPubMed
Sak, D, Erdenen, F, Müderrisoglu, C, et al. (2019) The relationship between plasma taurine levels and diabetic complications in patients with type 2 Diabetes mellitus. Biomolecules 9, 96.CrossRefGoogle ScholarPubMed
Tao, X, Zhang, Z, Yang, Z et al. (2022) The effects of taurine supplementation on diabetes mellitus in humans: a systematic review and meta-analysis. Food Chem 4, 100106.Google ScholarPubMed
Moloney, MA, Casey, RG, O’Donnell, DH, et al. (2010) Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc Dis Res 7, 300–310.CrossRefGoogle ScholarPubMed
Premanath, M, Mahesh, M, Babu, M, et al. (2019) Can N acetyl cysteine – taurine provide additional reduction in microalbuminuria in type 2 diabetic patients already on optimum doses of angiotensin converting enzyme inhibitors? Int J Health Allied Sci 8, 236–241.CrossRefGoogle Scholar
Samadpour, MS, Bagheri, R, Ashtary-Larky, D, et al. (2021) The effects of TRX suspension training combined with taurine supplementation on body composition, glycemic and lipid markers in women with type 2 diabetes. Nutrients 13, 3958.CrossRefGoogle Scholar
Esmaeili, F, Maleki, V, Kheirouri, S, et al. (2021) The effects of taurine supplementation on metabolic profiles, pentosidine, soluble receptor of advanced glycation end products and methylglyoxal in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Can J Diabetes 45, 39–46.CrossRefGoogle ScholarPubMed
Svarovskaya, A & Garganeeva, A (2018) Evaluation of the effect of taurine on the course of coronary artery disease associated with diabetes of the 2nd type, in patients undergoing coronary revascularization. Medical Council 16, 94–99.Google Scholar
Chauncey, KB, Tenner, TE, Lombardini, JB, et al. (2003) The effect of taurine supplementation on patients with type 2 diabetes mellitus. In Taurine 5, Advances in Experimental Medicine and Biology, vol. 526. pp. 91–96 [Lombardini, JB, Schaffer, SW & Azuma, J, editors]. Boston, MA: Springer US.Google Scholar
Chan, A-W, Tetzlaff, JM, Altman, DG, et al. (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 158, 200–207.CrossRefGoogle ScholarPubMed
Mizushima, S, Nara, Y, Sawamura, M, et al. (1996) Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Adv Exp Med Biol 403, 615–622.CrossRefGoogle ScholarPubMed
Schwarzer, R, Kivaranovic, D, Mandorfer, M, et al (2018) Randomised clinical study: the effects of oral taurine 6 g/d v. placebo on portal hypertension. Aliment Pharmacol Ther 47, 86–94.CrossRefGoogle Scholar
Pinto, MB, Bock, PM, Schein, ASO, et al. (2021) Inspiratory muscle training on glucose control in diabetes: a randomized clinical trial. Int J Sport Nutr Exerc Metab 31, 21–31.CrossRefGoogle ScholarPubMed
Abramson, JH (2011) WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov 8, 1.CrossRefGoogle ScholarPubMed
Matthews, DR, Hosker, JP, Rudenski, AS, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419.CrossRefGoogle ScholarPubMed
Hill, NR, Oliver, NS, Choudhary, P, et al. (2011) Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 13, 921–928.CrossRefGoogle ScholarPubMed
Ministério da Saúde (2012) Resolução No 466, de 12/12/2012, Diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos (Resolution No 466, de 12/12/2012, Guidelines and regulatory standards for research on human beings). Diário Oficial da União. https://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html (accessed August 2022).Google Scholar
Chen, W, Guo, J, Zhang, Y, et al. (2016) The beneficial effects of taurine in preventing metabolic syndrome. Food Funct 7, 1849–1863.CrossRefGoogle ScholarPubMed
Imae, M, Asano, T & Murakami, S (2014) Potential role of taurine in the prevention of diabetes and metabolic syndrome. Amino Acids 46, 81–88.CrossRefGoogle ScholarPubMed
Zhang, M, Bi, LF, Fang, JH, et al. (2004) Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids 26, 267–271.CrossRefGoogle ScholarPubMed
Zhang, Y, Hu, G, Yuan, Z, et al. (2012) Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 7, e42551.CrossRefGoogle ScholarPubMed
Saed, L, Deihim, Z, Naghshbandi, MK, et al. (2019) Cardiovascular events in patients with over 10 years history of type 2 diabetes mellitus. Diabetes Metab Syndr 13, 68–72.CrossRefGoogle ScholarPubMed
Schaffer, SW, Azuma, J & Mozaffari, M (2009) Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 87, 91–99.CrossRefGoogle ScholarPubMed
Baliou, S, Adamaki, M, Ioannou, P, et al. (2021) Protective role of taurine against oxidative stress (Review). Mol Med Rep 24, 1–19.CrossRefGoogle ScholarPubMed
Qaradakhi, T, Gadanec, LK, McSweeney, KR, et al. (2020) The anti-inflammatory effect of taurine on cardiovascular disease. Nutrients 12, E2847.CrossRefGoogle ScholarPubMed